FGFR4 and colorectal carcinoma: In CRC, CAF-derived CCL2 upregulates FGFR4, which plays a role in tumor-matrix interactions and promotes EMT, which may constitute an essential factor in CRC resistance to 5-FU and oxaliplatin [294].